iQ Biosciences

About iQ Biosciences

This author has not yet filled in any details.
So far iQ Biosciences has created 29 blog entries.

Choosing Isotype Controls for ADC Studies: Wild-Type or Fc-Silent?

In an antibody-drug conjugate (ADC) experiment, the choice of isotype control shapes how clearly target-specific activity can be separated from background. An isotype control accounts for effects that are not specific to the target, which makes choosing the right one an important part of experimental design. Our previous blog post covered why a matched ADC isotype control matters and which properties should align with the molecule under study. This article builds on that foundation with a decision that gets less attention. When should an isotype control use a wild-type IgG1 backbone, and when should it be Fc-silent? The answer [...]

By |2026-09-17T09:30:49-07:00September 17th, 2026|Antibody-drug Conjugates, Bioconjugation, Blog|0 Comments
Read More

The Hidden Variable in Your ADC Experiment: Why Isotype Controls Must Match the Whole Molecule

Antibody-drug conjugates (ADCs) have made remarkable progress in recent years, combining the specificity of targeted antibodies with the potent cell-killing ability of cytotoxic payloads. As these molecules grow more structurally complex, the design of appropriate experimental controls must keep pace. A persistent challenge in ADC development is the continued use of standard unconjugated isotype controls in functional assays, including cytotoxicity, binding, and internalization, a practice that can produce misleading results when non-specific payload activity is misinterpreted as target-specific engagement. In this blog, we discuss the limitations of standard isotype controls in ADC experiments, outline the critical components of a properly [...]

By |2026-04-16T12:17:10-07:00April 16th, 2026|Antibody-drug Conjugates, Bioconjugation, Blog|0 Comments
Read More

The Suppressive Nature of Regulatory T Cells and Their Roles in Cancer and Diseases

Introduction to Regulatory T Cells The immune response is an exquisitely controlled event in which lymphocytes expand, secrete cytokines, and kill infected cells in response to foreign pathogens. At the peak of the immune response, extracellular organisms are eradicated through the humoral response, while intracellular pathogens are cleared by eliminating infected cells through the cellular response. In both cases, the activated immune cells will continue to look for pathogens or infected cells after clearance unless their response is regulated and culled. Without this diminishment of the immune response, unwanted events, such as non-specific destruction of tissue and organs, may [...]

By |2021-12-22T09:13:10-08:00December 20th, 2021|Bioservices, Blog, Regulatory T Cells (Tregs)|0 Comments
Read More

The ABCs of ADCs: An Introduction to Antibody-drug Conjugates

The terms “warhead” and “payload” typically invoke impressions of weapons and destruction. However, in a more constructive and positive light, these terms are now also commonly associated with antibody-drug conjugates (ADCs), a class of biologics used to treat cancer. These warheads and cytotoxic payloads are an integral part of ADCs that drive tumor cell death. Coupled to antibodies, ADCs combine the advantage of both modalities to be a potent class of anti-cancer molecules.In this blog, we will discuss the components that make up ADCs, what they are used for, and the future for this class of biologics. What [...]

By |2021-12-19T13:22:40-08:00June 18th, 2021|Antibody-drug Conjugates, Bioservices, Blog|0 Comments
Read More

ADCP: The Covert MoA for Therapeutic Antibodies You Need to Know About (Part 2)

In our previous blog, we discussed antibody-dependent cellular phagocytosis (ADCP), a mechanism of action for therapeutic antibodies that is becoming increasingly appreciated. In vitro and in vivo experiments show that ADCP, a process where phagocytic cells ingest and lyse opsonized target cells, can clear lymphoma cells in the presence of therapeutic antibodies.  To harness the potential of these antibodies, researchers have sought to determine the factors that influence ADCP. What are 3 currently known factors that can impact ADCP? Phagocytic Effector Cell Subtype - Like mentioned above, ADCP is performed by phagocytic cell types that include monocytes, macrophages, [...]

By |2021-12-22T09:15:31-08:00January 10th, 2019|Antibody-Dependent Cellular Phagocytosis, Bioservices, Blog|0 Comments
Read More

ADCP: The Covert MoA for Therapeutic Antibodies You Need to Know About (Part 1)

Therapeutic antibodies can work through various mechanisms of action.  They can inhibit ligand-independent dimerization to prevent downstream survival and proliferation signaling pathways or induce apoptosis of target cells.  In addition, therapeutic antibodies can activate the immune system to drive antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC) to eliminate aberrant cells.  However, one lesser known mechanism mediated by the immune system that is also driven by these antibodies is antibody-dependent cellular phagocytosis (ADCP). In this blog, we will introduce ADCP and discuss the data that supports its role in the anti-tumoral effects of therapeutic antibodies. What is antibody-dependent [...]

By |2021-12-22T09:15:54-08:00October 3rd, 2018|Antibody-Dependent Cellular Phagocytosis, Bioservices, Blog|0 Comments
Read More

Revisiting Complement, An Old Friend… (Part 3)

After summarizing how the complement system can have both anti-tumor and pro-tumor effects, we conclude our blog series on Reis et al. by discussing the clinical aspects of complement as a target and biomarker.  As discussed in the previous blogs, the imbalance in activation of complement leads to overproduction of complement proteins that causes a switch from immunosurveillance to tumorigenesis.  Thus, therapeutics may be developed that target complement proteins and fragments to restore balance and an effective immune environment. Using complement to enhance monoclonal antibody-based (mAb) therapies Engineering antibodies to enhance Fc region-mediated effector functions have been well [...]

By |2021-12-22T09:16:21-08:00June 5th, 2018|Bioservices, Blog, Complement-Dependent Cytotoxicity, In-Vitro Bioservices|0 Comments
Read More

Revisiting Complement, An Old Friend… (Part 2)

Complement in promotion of tumorigenesis. The imbalance and dysfunction of complement activity and activation can lead to various mechanisms that promote tumorigenesis. These mechanisms can have affects on the immune cells to provide a more favorable tumor growth environment, including: 1) recruitment of MDSCs, 2) suppression of effector T cell function, and 3) sustained release of pro-inflammatory factors for favorable tumor growth. In addition, loss of complement regulation has affects on non-immune cells that sustain tumor growth and metastasis, including: 1) angiogenesis, 2) abnormal tumor cell proliferation, and 3) cell invasion and metastasis. Please see our blogs for more [...]

By |2021-12-22T09:16:52-08:00April 24th, 2018|Bioservices, Blog, Complement-Dependent Cytotoxicity, In-Vitro Bioservices|0 Comments
Read More

Revisiting Complement, An Old Friend… (Part 1)

The complement system of the innate immune system has been widely regarded as an early deterrent to infections and a means to clear pathogens by activating a group of proteins that leads to cell lysis, phagocytosis, and inflammation.  In addition, the power of complement has been implicated as a mechanism by which therapeutic antibodies, such as Rituxan, promoted their anti-tumor effects.  Along those lines, many biotechnology and pharmaceutical companies have tried to harness that power in targeted monoclonal antibody (mAb) cancer therapies.  However, more recent findings have indicated that, like everything about the immune system, balance is key and dysregulation [...]

By |2021-12-19T13:23:42-08:00March 13th, 2018|Bioservices, Blog, Complement-Dependent Cytotoxicity, In-Vitro Bioservices|0 Comments
Read More

T’ing it Up for Bi-Specific Antibodies…(Part 2)

In our previous blog, we discussed the two-predominant types of T cells, and some in vitro assays these cells are employed in to test the function and specificity of bi-specific antibodies.  In this blog, we discuss the in vivo assays that test the efficacy of these antibodies and tie it all together by reviewing some data generated with these assays. What are some T cell-based in vivo assays used to examine bi-specific antibody efficacy? Most preclinical in vivo experiments that examine the efficacy of bi-specific antibodies are performed using immuno-deficient mice, such as the NOD scid gamma (NSG) mice.  These mice [...]

By |2021-12-19T13:23:51-08:00January 9th, 2018|Bi-specific Antibody, Blog, T Cells|0 Comments
Read More

Let's save your cart!

Enter your email below and we'll save your cart for later!

Go to Top